SPOT ON, now is a call to action for all retail and any other insto who takes up a position on the register.
To the new insto's joining the ranks, vote no and extract a better offer and profit for yourselves, you will have many retail shareholders on your side backing you.
We all want to make money, not just Viburnum. Even with an improved offer many retail will still be well under in their investment and support of Mayne Pharma.
Was a sale on the cusp of a genuine turnaround a premature move from the board, I can't understand how that is extracting a good outcome for investors and maximising shareholder return? How was cancelling the share buy back full well knowing you were possibly negotiating a sale in the best interest of shareholders? The buy back would have provided stability to the SP.
MYX Price at posting:
$7.22 Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)